Suki Raises $90M Series E Financing for Healthcare AI

A clinician asking about a patient needs an answer that belongs to that patient. Suki is bringing chart information and clinical evidence into the same conversation, expanding the job of an assistant that earned its place by helping write the encounter down.

The Redwood City, California company announced $90M in financing as part of its Series E on October 13, 2026. New investors Healthier Capital, Crosslink Capital and Hercules Capital joined existing institutional backers, supporting a healthcare AI business that sells its own clinician application and supplies AI to other software companies.

That combination gives the financing an operating purpose beyond adding another feature to a documentation tool. Suki wants to carry information across clinical, financial and operational work, with distribution through both its own interface and its partners' products. Each route brings different people into the decision about how much work the assistant should do.

What Suki's Series E financing supports

The financing includes participation from existing investors Venrock, Flare Capital Partners, Hedosophia, Philips Ventures and Zoom Ventures. Suki did not identify a lead investor, disclose a valuation or break the $90M into equity and debt components. The company says the money will advance its AI technology, integrations, partner ecosystem and commercial organization.

Healthier Capital Partner Aman Mahajan will join Suki's board as part of the transaction. Bringing a physician and health-system leader into that conversation adds relevant experience to a company pursuing a larger role in clinical work. The announcement describes a prospective board appointment; it provides no reason to infer how individual investors negotiated the financing.

Suki's earlier capital provides some context for the scale of that ambition. Its October 2024 Series D was $70M, and an official January 2025 announcement reported $168M raised to that point after an investment from Zoom Ventures. The current release leaves an updated cumulative total unstated, so the useful comparison is the company's expanding remit, rather than a reconstructed lifetime figure.

Why the chart and the evidence belong together

Suki launched Ask on October 8, shortly before the financing announcement. Wolters Kluwer confirms that the feature brings patient-specific information and UpToDate Expert AI content into Suki for Clinicians across Epic, Oracle Health, athenahealth and MEDITECH. A clinician can retrieve details from a chart and access source-grounded clinical knowledge within the same working environment.

Those are related but distinct kinds of information. A medication list describes something about a particular person; clinical literature supplies evidence a clinician may need when assessing that person's care. Making both easier to retrieve can remove searching and copying from the working day. The commercial opportunity sits in that connection, where an application can become useful at another moment in the visit.

Suki describes Ask as information retrieval and synthesis, with clinicians responsible for reviewing the information and making care decisions. That boundary matters when considering the company's broader agent ambitions. A product can prepare information or work for review while responsibility remains with the professional using it, and the interface needs to make that division understandable in practice.

Two businesses share the clinical workflow

Founder and CEO Punit Soni's current leadership team includes CTO Joe Chang and CPO Abhi Pathak. Historical accounts also identify Karthik Rajan and Anshu Sharma as cofounders; neither is presented on the current official roster as an operating executive. Suki's company profile dates its founding to 2017, giving the present product expansion a history longer than the latest agent vocabulary.

The company now serves clinicians directly through its application while offering SDKs and APIs to technology partners. The SDK route includes prebuilt user interface components; APIs allow a partner more flexibility over its own interface and workflow. That choice lets a technology company decide how much of the integration and presentation it wants to own.

For Suki, the partner route creates a commercial relationship with somebody who has a customer relationship of their own. The partner's product managers have to decide how a generated note, patient summary or staged order fits the product they sell. This makes integration quality part of distribution: the supplier's capability must become useful inside another team's decisions about screens, permissions and user habits.

Adoption puts the expansion in perspective

Suki reports that more than 450 healthcare organizations use its clinician application and more than 30 technology partners embed its AI. The company also reports more than 10x growth in partner revenue over 2 years. Those are company-reported measures, but they explain why the embedded route deserves attention alongside the application carrying Suki's name.

A more specific deployment account comes from Austin Regional Clinic's July announcement with Suki. The organizations reported an 18.5% reduction in documentation time per encounter and 97% engagement among onboarded clinicians. The figures describe that implementation; they should travel with their customer context rather than become a promise about every deployment.

Other healthcare software investments illuminate the neighboring work. DevCuration's coverage of Brellium's clinical-note review expansion and Intake AI's clinical-trial operations follows different parts of the information lifecycle. For a buyer, those distinctions help separate products by the work they perform and the people expected to review their output.

More work reaches the approval screen

Suki's clinician product already describes order staging that prepares proposed orders for review and approval. That is a concrete example of the company's movement from recording an encounter toward helping carry out the work around it. The proposed action still arrives at a clinician who must understand what has been prepared.

The Series E financing supports the technology and commercial capacity behind that expansion. As Suki and its partners put additional capabilities into familiar healthcare software, product teams will keep deciding how context, evidence and approval meet on the screen a clinician actually uses. The assistant's next useful job begins inside that shared design work.